quite a large sub group of men with recurrent prostate cancer were able to put off psa rises and put off mets developing and reduce psa with no hornone treatment just Olaparib - LYNPARZA
in short, the responders, who can be tested by gene typing, had median time of almost 4 years without adt vs the non responders who only managed 12 months - AFTER recurrence. One of the gene types is BRCA.
Olaparib monotherapy is very effective for metastatic castration-resistant prostate cancer. ascopubs.org/doi/full/10.12... I see no reason why it should not be effective for hormone sensitive prostate cancer patients, provided a BRCA mutation has been determined. I think you can remove the "may be" in the headline of the report. However, Olaparib has no FDA approval for hormone sensitive prostate cancer patients yet.
This PARP inhibitor study regards Biochemical Recurrence (BCR) stage. The next study should be combination therapy, Parp + the standard (EMBARK study) for high risk BCR, double hormone blockade (ADT {Lupron} + ARSI{Enzalutamid}) vs. double hormone therapy in the control arm.
I'm BRCA2 and this is good and bad news. I'm on a Facebook group for the drug and 90% of the women are beyond miserable. That being said, I'm thankfull that I got the blood test from the beginning.
the more serious side effects sound brutal
Pembrolizumab in Patients With Heavily Treated Metastatic Castration-Resistant Prostate Cancer 
Brachytherapy Combined With or Without Hormone Therapy for Localized Prostate Cancer.
T Therapy in men with APCBipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide.Prostate cancer ‘super responders’ live for two years on immunotherapy
